◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › S › SRPT

Sarepta Therapeutics Inc (SRPT) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-06

Sarepta Therapeutics Inc (SRPT) operates in the BIOTECHNOLOGY industry and is headquartered in Cambridge, United States with about 835 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, SRPT reported $2.2B in revenue and ($713M) in net income.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.

Interactive charts & full statements → Open the SRPT valuation workbench →

SRPT Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$2.0B	$2.2B	$1.9B	$1.2B	$933M	$702M	$540M	$381M	$301M	$155M	$5M	$1M	$10M	$14M	$37M	$47M	$29M	$18M	$21M	$11M	$0M
Gross Profit	$1.2B	$1.3B	$1.6B	$1.1B	$793M	$605M	$477M	$324M	$267M	$147M	$5M	$1M	($84M)	($76M)	($15M)	$11M	$2M	$18M	$21M	$11M	$0M
Gross Margin %	58.6%	59.9%	83.2%	87.9%	85.0%	86.2%	88.3%	85.1%	88.6%	95.2%	97.6%	100.0%	-864.5%	-535.0%	-39.1%	23.5%	6.7%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($144M)	($658M)	$218M	($268M)	($536M)	($460M)	($564M)	($706M)	($344M)	($172M)	($267M)	($220M)	($134M)	($90M)	($30M)	($36M)	($21M)	($16M)	($27M)	($33M)	($33M)
Operating Margin %	-7.3%	-29.9%	11.5%	-21.5%	-57.5%	-65.5%	-104.5%	-185.3%	-114.1%	-111.0%	-4920.3%	-17572.6%	-1371.2%	-635.0%	-79.6%	-76.5%	-71.2%	-88.2%	-129.2%	-301.4%	-28608.5%
Net Income	($137M)	($713M)	$235M	($536M)	($703M)	($419M)	($554M)	($715M)	($362M)	($51M)	($267M)	($220M)	($136M)	($112M)	($121M)	($2M)	($32M)	($25M)	($24M)	($27M)	($31M)
Net Margin %	-6.9%	-32.5%	12.4%	-43.1%	-75.4%	-59.7%	-102.6%	-187.8%	-120.2%	-32.8%	-4930.2%	-17560.3%	-1391.7%	-787.6%	-324.9%	-4.9%	-109.4%	-143.1%	-112.7%	-247.3%	-26951.8%
EBITDA	($15M)	($648M)	$317M	($454M)	($595M)	($317M)	($453M)	($659M)	($317M)	($35M)	($261M)	($215M)	($130M)	($88M)	($28M)	($35M)	($19M)	($14M)	($22M)	($25M)	($31M)
Earnings Per Share (EPS)	$-1.84	$-6.81	$2.18	$-5.80	$-8.03	$-5.15	$-7.11	$-9.71	$-5.46	$-0.86	$-5.49	$-5.20	$-3.39	$-3.31	$-5.14	$-0.11	$-1.74	$-1.62	$-2.07	$-3.02	$-3.54
Shares Outstanding (M)	105M	105M	108M	92M	88M	81M	78M	74M	66M	59M	49M	42M	40M	34M	24M	22M	19M	16M	12M	9M	9M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SRPT Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$401M	$731M	$443M	$399M	$611M	$745M	$658M	$467M
Gross Profit	$252M	$611M	$44M	$249M	$459M	$607M	$526M	$375M
Gross Margin %	62.8%	83.7%	10.0%	62.3%	75.0%	81.5%	79.9%	80.4%
Operating Income (EBIT)	$13M	$358M	($412M)	($103M)	$116M	($300M)	$162M	$22M
Operating Margin %	3.3%	49.0%	-92.9%	-25.9%	18.9%	-40.3%	24.6%	4.8%
Net Income	($5M)	$331M	($283M)	($180M)	$197M	($448M)	$159M	$34M
Net Margin %	-1.2%	45.3%	-63.9%	-45.1%	32.2%	-60.1%	24.2%	7.2%
EBITDA	$30M	$375M	($252M)	($168M)	$170M	($369M)	$187M	$49M
Earnings Per Share (EPS)	$-0.05	$2.71	$-2.70	$-1.80	$1.85	$-4.60	$1.47	$0.33
Shares Outstanding (M)	105M	122M	105M	100M	107M	97M	108M	100M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SRPT Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$110M	($205M)	($206M)	($501M)	($325M)	($443M)	$107M	($456M)	($389M)	($232M)	($246M)	($149M)	($129M)	($65M)	($30M)	($24M)	($15M)	($9M)	($12M)	($25M)	($21M)
Capital Expenditures (CapEx)	$37M	$102M	$147M	$87M	$32M	$38M	$82M	$60M	$64M	$21M	$7M	$5M	$27M	$4M	$1M	$2M	$2M	$2M	$1M	$2M	$1M
Free Cash Flow (FCF)	$74M	($307M)	($353M)	($588M)	($358M)	($482M)	$25M	($516M)	($453M)	($253M)	($253M)	($154M)	($155M)	($68M)	($31M)	($26M)	($17M)	($11M)	($14M)	($27M)	($22M)
FCF Margin %	3.8%	-14.0%	-18.6%	-47.3%	-38.3%	-68.6%	4.7%	-135.5%	-150.5%	-163.8%	-4661.2%	-12314.3%	-1592.3%	-481.5%	-82.6%	-55.3%	-58.3%	-61.4%	-63.8%	-244.0%	-19140.5%
Dividends Paid	—	—	—	—	—	—	$286M	$241M	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SRPT Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$197M	($203M)	$131M	($15M)	$261M	($583M)	$92M	($71M)
Capital Expenditures (CapEx)	$0M	$3M	$6M	$28M	$32M	$46M	$38M	$37M
Free Cash Flow (FCF)	$198M	($206M)	$125M	($43M)	$229M	($629M)	$54M	($108M)
FCF Margin %	49.4%	-28.2%	28.3%	-10.7%	37.5%	-84.5%	8.2%	-23.1%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SRPT Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$3.2B	$3.4B	$4.0B	$3.3B	$3.1B	$3.1B	$3.0B	$1.8B	$1.6B	$1.3B	$424M	$274M	$295M	$292M	$205M	$54M	$46M	$60M	$26M	$39M	$41M
Cash & Cash Equivalents	$571M	$801M	$1.1B	$428M	$967M	$2.1B	$1.5B	$835M	$371M	$600M	$122M	$80M	$74M	$257M	$188M	$40M	$34M	$48M	$11M	$25M	$20M
Total Liabilities	$1.7B	$2.2B	$2.4B	$2.4B	$2.7B	$2.2B	$2.2B	$1.0B	$610M	$519M	$87M	$83M	$47M	$44M	$81M	$23M	$49M	$36M	$10M	$12M	$3M
Total Debt (Short + Long-Term)	$848M	$840M	$1.2B	$1.3B	$1.6B	$1.4B	$1.2B	$690M	$555M	$431M	$16M	$23M	$6M	($8M)	$2M	$2M	$2M	$2M	$2M	$2M	$0M
Total Shareholders' Equity	$1.5B	$1.1B	$1.5B	$859M	$385M	$928M	$762M	$818M	$1.0B	$789M	$337M	$190M	$248M	$247M	$124M	$31M	($3M)	$24M	$16M	$26M	$38M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SRPT viewer.

Other Companies in BIOTECHNOLOGY

GENB · Generate Biomedicines, Inc. Common Stock — $2 billion
OCUL · Ocular Therapeutix Inc — $2 billion
PVLA · Palvella Therapeutics, Inc — $2 billion
TRVI · Trevi Therapeutics Inc — $2 billion
URGN · UroGen Pharma Ltd — $2 billion
BHVN · Biohaven Ltd. — $2 billion
KOD · Kodiak Sciences Inc — $2 billion
NUVB · Nuvation Bio Inc — $2 billion

← SRP All “S” companies SRRK →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.